Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

This week's roundup includes high level appointments by Merck KGaA, Chromocell Corporation, Kymab and GW Pharmaceuticals, in addition to board appointments by Fortuna Fix and Motif Bio.

Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.

Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.